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Objective: To assess the association between human T-lymphotropic virus type 1 (HTLV-1) infection and
onychodystrophy.
Methods: This was a cross-sectional study. At our institute, we provide HTLV-1 testing to relatives of
HTLV-1-infected people and patients with suspected HTLV-1-associated diseases. The diagnosis of
onychodystrophy was made clinically before testing for HTLV-1; the number and distribution of affected
nails was registered. We assessed the association between onychodystrophy and HTLV-1 through bi- and
multivariable analyses. Logistic regression was used to adjust for age, sex, and indication for HTLV-1
testing, using six affected nails (90th percentile) as the cut-off point.
Results: Between April 2006 and March 2008, we included 893 subjects; their mean age was 38 years
(standard deviation 19 years), and 527 (59%) were women. Onychodystrophy of one or more nails was
observed in 323 participants (36%), and 236 subjects (26%) were HTLV-1-positive. The median number of
affected nails was higher in HTLV-1-positive than in HTLV-1-negative subjects (Mann–Whitney test, p <
0.001). Thirty-eight of 97 subjects with six or more affected nails (39%) were HTLV-1-infected, compared
to 198 of 796 subjects with fewer than six affected nails (25%) (crude OR 1.9, 95% conﬁdence interval (CI)
1.2–3.1; p = 0.003). This association remained signiﬁcant in the multiple logistic regression model
(adjusted OR 2.0, 95% CI 1.2–3.3; p = 0.005).
Conclusions: There is an independent association between HTLV-1 infection and onychodystrophy.
Patients with an HTLV-1 infection might have a higher risk for onychomycosis given the abnormal nail
plate and a decreased T-cell-mediated immunologic response.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Human T-lymphotropic virus type 1 (HTLV-1) is associated
with a wide range of clinical manifestations that vary notably in
frequency, pathogenesis, clinical presentation, and severity.1 Even
if there is incomplete understanding of all the diseases that can
occur in the context of HTLV-1 infection, an estimated 10% of
people will develop a clinical manifestation throughout life.1
HTLV-1-associated diseases include lymphoproliferative, in-
ﬂammatory, and infectious disorders, among which adult T-cell* Corresponding author.
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cal spastic paraparesis (HAM/TSP), and infective dermatitis remain
the better known, but no longer the only ones. In spite of
heterogeneous consistency and quality, increasing evidence
continues to expand the list of HTLV-1-associated diseases, many
of which affect the skin. Infective dermatitis is the most
characteristic skin condition seen in people with HTLV-1 infection,
but dermatophytosis, seborrheic dermatitis, and acquired ichthyo-
sis also occur more frequently in those with an HTLV-1 infection
than in those without HTLV-1.2 Interestingly, HTLV-1 infection is
more common in people with skin lesions than in people without.3
The interaction between HTLV-1 and the host’s immune system
ultimately compromises normal T-cell function and seems to
underlie some mechanisms that can eventually put the hostses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline characteristics (N = 893)




Test indication, n (%)
Close relative of a person with HTLV-1 infection 428 (47.9)
Neurological disorder 118 (13.2)
Strongyloidiasis 160 (17.9)
Othera 187 (21.0)






a Indication for HTLV-1 testing was dermatitis for 52 (27.8%), skin infection for 43
(23.0%), uveitis for 18 (9.6%), to rule out malignancy for 15 (8.0%), work-up for
autoimmune diseases for 14 (7.5%), to rule out tuberculosis for nine (4.8%), being a
close relative of a child with a disease possibly linked to HTLV-1 for seven (3.7%),
skin lesions for seven (3.7%), to rule out mycosis fungoides for six (3.2%), other
infections for four (2.1%), work-up for an immune suppression state for four (2.1%),
accidental needle stick injury for three (1.6%), work-up for sexually transmitted
infections for three (1.6%), sexual contact with somebody with HTLV-1 infection for
one (0.5%), and pregnancy for one (0.5%).
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infections. HTLV-1 primarily infects T lymphocytes, inducing the
expression of the viral protein Tax.1 Tax functions both as mitogen
and antigen and interferes with the natural cycle of the
lymphocyte: it drives T-cells into proliferation4 and at the same
time exposes them to a cytotoxic T-cell response.5 Furthermore,
HTLV-1 induces the production of CD4+ CD25+ FoxP3+ (regulatory)
T-cells, which may decrease the body’s ability to cope with
infections.6 Not surprisingly, several opportunistic infections have
been described in people with HTLV-1, including scabies,7
strongyloidiasis,8 and tuberculosis.9
Onychomycosis, a fungal infection of the nail plate, is a common
condition in the case of cellular immune dysfunction, e.g. in people
with HIV infection,10 diabetes mellitus type 2,11 and psoriasis.12 At
our institute in Peru, a country where HTLV-1 infection is endemic,
affecting between 1% and 2% of the general population,13 we have
found that some HTLV-1-infected patients do present with
extensive onychomycosis. All these elements together led us to
hypothesize that HTLV-1 infection predisposes to onychomycosis,
a ﬁnding that to our knowledge has not yet been reported in the
literature by other groups, and this work is part of the ﬁrst step to
evaluate such a possible association.
2. Materials and methods
This cross-sectional study was done at the Instituto de Medicina
Tropical ‘‘Alexander von Humboldt’’ (IMT) of the Universidad
Peruana Cayetano Heredia (UPCH), afﬁliated to the Department of
Infectious and Tropical Diseases of the Hospital Nacional Cayetano
Heredia, a public, tertiary level hospital in Lima. Since 1990, this
institute has offered free HTLV-1 testing primarily to three patient
groups: those for whom there is a clinical suspicion of an HTLV-1-
associated disease, close relatives of HTLV-1-infected persons, and
candidate blood donors who have initial positive results on HTLV
blood bank screening tests.
For this study, we used the data from adult subjects who agreed
to participate in the ongoing HTLV-1 cohort study at IMT between
April 2006 and March 2008 and who were not aware of their HTLV
status at the time of enrolment in the cohort study (i.e., we
excluded HTLV-seropositive candidate blood donors). Additional
exclusion criteria were indeterminate serology for HTLV, presence
of known risk factors for onychomycosis (HIV infection or
psoriasis), incomplete information on the status of the nails, and
onychomycosis as the main indication for HTLV-1 testing.
At the time of enrolment in the cohort study, before the
examiners and examinees knew the HTLV status, all subjects
underwent the same standardized evaluation performed by
trained health staff: an interview and a basic clinical evaluation.
As part of the latter, ﬁnger and toe nails were assessed for the
clinical diagnosis of onychodystrophy and the examiner recorded
the number of nails affected.
Serology for HTLV-1 was performed by ELISA using three
commercial kits (Murex1, Ortho1, and Platelia1). The result was
considered positive when two ELISA tests were reactive. In the case
of indeterminate or discordant ELISA results, the infection status
was determined by Western blot or Innolia1.14
On a routine basis, the information was anonymously entered
into the cohort database, which was subject to periodic quality-
control checks. Regarding the deﬁnition of ethnic origin, we
considered the origin to be Andean if both parents or if the four
grandparents were born in the Andean region and their mother
tongue was Quechua (a native language of the Peruvian Andes), as
Mestizo if one of the parents or grandparents was born outside the
Andean region, and as ‘other’ ethnic origin if the participant was of
Caucasian, black, or oriental descent.For this analysis, we evaluated the proportion of people with
involved nails, comparing HTLV-1-positive and HTLV-1-negative
groups with the Chi-square test. The difference in the number of
nails involved between these two groups was assessed with the
Mann–Whitney test. We then conducted logistic regression
analyses to calculate the odds of having HTLV-1 among those
people with onychodystrophy versus those without. Having at
least one nail with onychodystrophy was a frequent event in
the study population; therefore, we chose a more extended
manifestation of the disease to summarize our results. Taking into
account that 10% of the participants had six or more affected nails,
we reported the results using six or more affected nails as the cut-
off point, however we repeated the logistic regression analyses
using different cut-off points. To adjust the odds ratio of HTLV-1 for
age, sex, indication for HTLV testing, and ethnicity, we did multiple
logistic regression analyses. Some of the included subjects were
related to each other and observations coming from the same
family may not be independent. To adjust for the possible
clustering of characteristics within families, we used generalized
estimating equations. Analyses were done using STATA statistical
package version 10.0 (UPCH Epidemiology Unit). Odds ratios (OR)
are reported with 95% conﬁdence intervals (95% CI).
The study protocol was revised and approved by the
Institutional Ethics Committee at UPCH.
3. Results
During the study period, 1012 subjects were tested for HTLV-1
for the ﬁrst time at our institute. We excluded the information of
119 (11.8%) participants for the following reasons: 66 (55.5%) had
incomplete basic clinical evaluations, 48 (40.3%) had a known HIV
infection, four (3.4%) were tested for HTLV-1 because they had
onychomycosis, and one (0.8%) had psoriasis. We included
information from 893 participants; their mean age was 38 years
(standard deviation 19 years), and 527 (59.0%) were women. Being
a close relative of a person with an HTLV-1 infection was the most
frequent indication for HTLV testing (47.9%), followed by having
strongyloidiasis (17.9%) and having neurological problems (13.2%).
The remaining participants (21.0%) came for other reasons
(Table 1).
Table 2
Clinical characteristics (N = 893)
Characteristics Total participants HTLV-1-positive HTLV-1-negative
Number of affected nails, n (%)
None 570 (63.8) 130 (22.8) 440 (77.2)
1 323 (36.2)a 106 (32.8) 217 (67.2)
2 243 (27.2)a 82 (33.7) 161 (66.3)
3 164 (18.4)a 57 (34.8) 107 (65.2)
4 133 (14.9)a 50 (37.6) 83 (62.4)
5 107 (12.0)a 41 (38.3) 66 (61.7)
6 97 (10.9)a 38 (39.2) 59 (60.8)
7 84 (9.4)a 34 (40.5) 50 (59.5)
8 75 (8.4)a 30 (40.0) 45 (60)
9 63 (7.1)a 25 (39.7) 38 (60.3)
10 52 (5.8)a 21 (40.4) 31 (59.6)
Toenail onychodystrophy, n (%)
No 584 (65.4) 137 (23.5) 447 (76.5)
Yes 309 (34.6) 99 (32.0) 210 (68.0)
Fingernail onychodystrophy, n (%)
No 844 (94.5) 216 (25.6) 628 (74.4)
Yes 49 (5.5) 20 (40.8) 29 (59.2)
a This percentage considers 893 participants as 100%. Figure 1. Comparison of the odds ratios and conﬁdence intervals of having a
positive serology for HTLV-1 based on the minimum number of dystrophic nails.
Figure 2. Comparison of the odds ratios and conﬁdence intervals of having a
positive serology for HTLV-1 based on the minimum number of dystrophic nails,
adjusted for sex, age, indication for the test and ethnic background.
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either their ﬁnger or toe nails; 309 (34.6%) had onychodystrophy in
toenails only and 49 (5.5%) in ﬁngernails only. Two hundred thirty-
six participants (26.4%) were HTLV-1-positive (Table 2).
Participants with HTLV-1 had more nails with onychodystrophy
compared with those who were HTLV-1-negative (Mann–Whitney
test, p < 0.001). This difference was also signiﬁcant when
involvement of the feet (p = 0.002) and hands (p = 0.02) was
analyzed separately.
Thirty-eight out of 97 (39.2%) subjects with six or more affected
nails were positive for HTLV-1 infection, compared with 198 out of
796 participants (24.9%) with fewer than six affected nails (crude
OR 1.9, 95% CI 1.2–3.1; p = 0.003). The mean age was greater among
participants with onychodystrophy (50.6  14.8 years) than in
those without onychodystrophy (36.5  19 years). On bivariate
analyses, onychodystrophy was associated with older age and
Andean ethnic background. Regarding the indication for HTLV
testing, people with neurological disorders were overrepresented
in the group of people with onychodystrophy, whereas relatives of
people with HTLV-1 were more frequent in the group of people
without onychodystrophy. Nevertheless, all these bivariate associa-
tions lost statistical signiﬁcance when age was added to the
multivariable analysis (Table 3). The association between onycho-
dystrophy and HTLV-1 infection remained signiﬁcant in a model ofTable 3
Characteristics of participants with at least six affected nails (‘onychodystrophy’) compared to participants with ﬁve or fewer affected nails (‘no onychodystrophy’)
Onychodystrophy No onychodystrophy Total Crude OR 95% CI Adjusted OR 95% CI
HTLV-1, n (%)
Positive 38 (39.2) 198 (24.9) 236 (26.4) 1.9 1.2–3.08 2.0 1.2–3.28
Negative 59 (60.8) 598 (75.1) 657 (73.6)
Age, years, mean  SD 50.6  14.8 36.5  19 38  19.2 1.03 1.03–1.05 1.04 1.02–1.05
Gender, n (%)
Male 44 (45.4) 322 (40.5) 366 (41.0)
Female 53 (54.6) 474 (59.5) 527 (59.0) 1.2 0.8–1.9 1.3 0.8–2.1
Test indication, n (%)
Close relative of a person with HTLV-1 infection 31 (32.0) 397 (49.9) 428 (47.9) 0.5 0.3–0.7 0.6 0.3–1.1
Neurological disorder 20 (20.6) 98 (12.3) 118 (13.2) 1.8 1.1–3.2 0.9 0.5–2.0
Strongyloidiasis 24 (24.7) 136 (17.1) 160 (17.9) 1.6 0.9–2.6 1.6 0.8–3.1
Other 22 (22.7) 165 (20.7) 187 (21.0)
Ethnic origin, n (%)
Andean 67 (69.1) 439 (55.2) 506 (56.7) 1.8 1.2–2.9 1.4 0.8–2.4
Mestizo 25 (25.8) 292 (36.7) 317 (35.5) 0.6 0.4–0.9 0.9 0.3–2.9
Other 5 (5.1) 48 (6.0) 53 (5.9)
Unknown 0 17 (2.1) 17 (1.9)
SD, standard deviation; OR, odds ratio; CI, conﬁdence interval.
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infection, participant age, sex, and indication for HTLV testing
(adjusted OR 2.0, 95% CI 1.2–3.3; p = 0.005). Moreover, it also
remained signiﬁcant when we considered different numbers of
affected nails as cut-off points (Figures 1 and 2).
Our population of 893 participants came from 625 families.
When this element was incorporated into the multivariable model,
the association between HTLV-1 and onychodystrophy also
remained signiﬁcant (adjusted OR 1.9, 95% CI 1.2–3.2).
4. Discussion
In this study we investigated a possible association between
HTLV-1 infection and onychodystrophy. By analyzing data from
893 participants of a Peruvian cohort of people tested for HTLV-1,
we demonstrate that such an independent association does exist.
This association remained signiﬁcant using different numbers of
nails with onychodystrophy as cut-off points, whereas the odds of
HTLV-1 infection increased as there were more nails involved.
One of the most important causes of onychodystrophy is
onychomycosis. This condition is extremely common in our
population.15 For this reason, we consider that onychomycosis
could be included among the group of infections that can affect
people with HTLV-1, such as scabies,7 strongyloidiasis,8 and
tuberculosis.9
This association between HTLV-1 infection and onychomy-
cosis may have its basis in the poor immune response mediated
by T-cells induced by HTLV-1 infection. The control of fungal
infections of the nail bed relies on the T-cell-dependent cellular
immune response.16,17 It has been shown that people with a
robust cellular immune response can eliminate the fungus,
whereas those who are not able to mount this line of defense
appropriately are prone to a chronic infection.18 This decreased
immune response in patients with onychomycosis has also been
found when measuring the skin reaction to dermatophyte
antigens.19 In fact, co-infection with dermatophytes and HIV is
widely recognized,10 as is the severe decrease in the cellular
response that characterizes the progression of HIV.
Notably, the risk of onychomycosis is associated with fewer
CD4+ T-cells.20
Of interest, it has been reported that patients with HTLV-1 have
a decreased response to the tuberculin skin test,21 which is a cell-
mediated hypersensitivity reaction. This immunological phenom-
enon probably has a signiﬁcant clinical impact: in Peru and Brazil,
persons with tuberculosis have been shown to have HTLV-1
infection more often than the general population.9 Also, persons
living with HTLV-1 infection have a higher risk of developing
tuberculosis.22 We have found some case reports that describe
HTLV-1 infection among severe cases of fungal infections,23 but
evidence in that regard is still scarce.
In the framework of a cross-sectional study, we certainly cannot
assess or conclude that HTLV-1 infection precedes onychomycosis.
However, the endemicity of HTLV-1 is considered to be sustained
mainly by breastfeeding and subsequent mother-to-child trans-
mission, so it is reasonable to expect that a great number of
participants were actually infected during infancy.24 In addition, it
is noteworthy that the odds of having HTLV-1 tend to increase as
more nails are involved (Figures 1 and 2), as if this more extended
spectrum of disease acts like a red ﬂag for an immune suppression
state in the patient.
In terms of the limitations of this study, the diagnosis of
onychomycosis was established by different observers, on clinical
grounds only, without conﬁrmation by microscopy or culture.
However, this may have had little effect on our results. This
diagnostic approach took place before the results of serology were
known and remained restricted to persons who had not previouslyhad an HTLV-1 test. This approach probably did not introduce
differences between participants with and without HTLV-1
infection. Finally, we did not assess HIV infection in the whole
sample, although we excluded those participants with a positive
HIV result. In contrast to other settings in which the majority of
HTLV-1 infections are seen in intravenous drug users, the
proportion of people with HTLV-1 and HIV co-infection is a
minority at the IMT, and we thus anticipate that the number of
missed HIV infections was probably low and did not affect our
ﬁndings.22
We conclude that in this setting, characterized by high rates of
HTLV-1 and onychomycosis, these infections might be associated.
While consistent demonstration of causation requires further
studies, we consider this study a ﬁrst step towards demonstrating
that HTLV-1 infection increases the risk of having onychomycosis.
Therefore, we suggest that an underlying HTLV-1 infection should
be considered in the clinical care of patients with onychomycosis,
particularly when multiple nails are affected, and especially when
dealing with a population with a known high incidence of
seropositivity to this virus.
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